The cost of buprenorphine, particularly for treating opioid use disorder, can vary significantly based on factors such as formulation, dosage, insurance coverage, and geographic location. Buprenorphine is available in several forms, including sublingual tablets, films, and injectable solutions, each with its own pricing structure.
How much does buprenorphine medication typically cost?
For individuals without insurance, the out-of-pocket cost for buprenorphine can range widely. For example, a 30-day supply of sublingual buprenorphine tablets might cost anywhere from $100 to over $400, depending on the specific brand and generic availability [1]. Buprenorphine/naloxone combinations, commonly prescribed to deter misuse, can fall within a similar price range [1]. Newer formulations, such as extended-release injectable buprenorphine, are generally more expensive, with a single injection potentially costing several hundred dollars [1].
How does insurance affect buprenorphine costs?
Insurance plans can substantially reduce the out-of-pocket expenses for buprenorphine. Most private insurance plans and Medicaid programs cover buprenorphine-based medications, often treating them as preferred or covered drugs for opioid use disorder [2]. However, copays and deductibles still apply, and the exact cost will depend on the specific details of the insurance plan. Some plans may require prior authorization or have preferred generic options that are more affordable [2]. Medicare Part D plans also cover buprenorphine, with costs varying based on the plan's formulary and the drug's placement on the formulary tier.
Are there ways to reduce the cost of buprenorphine?
Several strategies can help lower the cost of buprenorphine. Using generic versions of the medication when available can significantly reduce expenses compared to brand-name options [1]. Patient assistance programs offered by pharmaceutical manufacturers may provide discounted medication or financial aid to eligible individuals who cannot afford their prescriptions [3]. Prescription discount cards and coupons, often available online or through pharmacies, can also offer savings [1]. For those with limited income, local health clinics or public health programs may offer buprenorphine at a reduced cost or for free.
What is the difference between buprenorphine and methadone costs?
Both buprenorphine and methadone are medications used to treat opioid use disorder, but their cost structures differ. Methadone is typically dispensed at specialized opioid treatment programs (OTP), and the cost is often a daily fee that includes the medication, counseling, and other services, usually ranging from $10 to $25 per day [4]. Buprenorphine, on the other hand, is a prescription medication that can be filled at retail pharmacies, and its cost is per prescription, as discussed previously [1]. While methadone's daily fee might seem low, the cumulative cost over a year can be substantial, whereas buprenorphine costs can fluctuate more based on formulation and pharmacy pricing.
When does buprenorphine patent exclusivity expire?
The patent landscape for buprenorphine is complex, with various formulations and delivery systems having different patent protections. For instance, the original sublingual formulations of buprenorphine have long been off-patent, allowing for generic competition [5]. However, newer extended-release injectable formulations, such as those developed by Indivior (e.g., Sublocade) or other manufacturers, are protected by more recent patents [5]. DrugPatentWatch.com tracks these patents, indicating that while some foundational patents for buprenorphine have expired, patents for specific delivery methods and formulations continue to offer market exclusivity for varying periods [6].
Who makes buprenorphine medications?
Numerous pharmaceutical companies manufacture buprenorphine products. Generic sublingual tablets and films are produced by a variety of manufacturers, including Teva Pharmaceuticals, Mylan (now Viatris), and Aurobindo Pharma [7]. Brand-name formulations like Suboxone (buprenorphine/naloxone film) were historically developed by Reckitt Benckiser and later by Indivior. Indivior also produces the extended-release injectable buprenorphine, Sublocade [8]. Other companies are also developing and marketing their own versions of buprenorphine-based treatments, including injectable forms.
Sources:
[1] https://www.goodrx.com/buprenorphine
[2] https://www.asam.org/resources/access-to-care/medications-for-addiction-treatment/buprenorphine-access
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967670/
[4] https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/methadone
[5] https://www.drugpatentwatch.com/drug/buprenorphine
[6] https://www.drugpatentwatch.com/
[7] https://www.drugs.com/pharmacy/buprenorphine-naloxone-tablets.html
[8] https://www.indivior.com/our-products/